Eyenovia Historical Income Statement
| EYEN Stock | USD 1.38 0.06 4.17% |
Historical analysis of Eyenovia income statement accounts such as Interest Expense of 2.9 M or Selling General Administrative of 7.3 M can show how well Eyenovia performed in making a profits. Evaluating Eyenovia income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Eyenovia's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Eyenovia latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Eyenovia is a good buy for the upcoming year.
Eyenovia |
About Eyenovia Income Statement Analysis
Eyenovia Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Eyenovia shareholders. The income statement also shows Eyenovia investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Eyenovia Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Eyenovia. It is also known as Eyenovia overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Eyenovia's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Eyenovia current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyenovia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.At this time, Eyenovia's Interest Income is very stable compared to the past year. As of the 23rd of March 2025, Depreciation And Amortization is likely to grow to about 945.7 K, while Selling General Administrative is likely to drop about 7.3 M.
| 2022 | 2023 | 2024 | 2025 (projected) | Depreciation And Amortization | 307.4K | 783.2K | 900.7K | 945.7K | Interest Income | 83.3K | 547.6K | 629.7K | 661.2K |
Eyenovia income statement Correlations
Click cells to compare fundamentals
Eyenovia Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eyenovia income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Income | 26.4K | 2.5K | 83.3K | 547.6K | 629.7K | 661.2K | |
| Depreciation And Amortization | 95.4K | 221.6K | 307.4K | 783.2K | 900.7K | 945.7K | |
| Interest Expense | 17.0K | 387.8K | 1.4M | 2.4M | 2.7M | 2.9M | |
| Selling General Administrative | 7.7M | 10.8M | 13.5M | 11.3M | 13.0M | 7.3M | |
| Total Revenue | 2M | 14M | 10M | 3.8K | 4.4K | 4.1K | |
| Gross Profit | 1.2M | 12.4M | (307.4K) | (783.2K) | (900.7K) | (855.7K) | |
| Other Operating Expenses | 21.8M | 26.9M | 26.9M | 25.4M | 29.2M | 18.6M | |
| Operating Income | (19.8M) | (12.9M) | (26.9M) | (25.4M) | (22.9M) | (24.0M) | |
| Net Income From Continuing Ops | (19.8M) | (12.8M) | (28.0M) | (25.4M) | (22.9M) | (24.0M) | |
| Ebit | (19.8M) | (12.4M) | (26.9M) | (24.9M) | (22.4M) | (23.5M) | |
| Research Development | 13.3M | 14.5M | 13.4M | 13.0M | 14.9M | 10.9M | |
| Ebitda | (19.7M) | (12.2M) | (26.6M) | (24.1M) | (21.7M) | (22.8M) | |
| Cost Of Revenue | 800K | 1.6M | 307.4K | 3.8K | 4.4K | 4.1K | |
| Total Operating Expenses | 21.0M | 25.3M | 26.9M | 25.4M | 29.2M | 18.3M | |
| Income Before Tax | (19.8M) | (12.8M) | (28.0M) | (27.3M) | (24.5M) | (25.8M) | |
| Total Other Income Expense Net | 19.4K | 125.3K | (1.1M) | (1.9M) | (1.7M) | (1.6M) | |
| Net Income Applicable To Common Shares | (17.3M) | (21.2M) | (19.8M) | (12.8M) | (11.5M) | (12.1M) | |
| Net Income | (19.7M) | (13.0M) | (27.7M) | (27.3M) | (24.5M) | (25.8M) | |
| Income Tax Expense | (78.4K) | 213.4K | (280.4K) | 2.0 | 1.8 | 1.89 | |
| Net Interest Income | 9.4K | (385.2K) | (1.3M) | (2.0M) | (1.8M) | (1.8M) | |
| Reconciled Depreciation | 95.4K | 221.6K | 307.4K | 584.2K | 671.8K | 705.4K |
Pair Trading with Eyenovia
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eyenovia position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eyenovia will appreciate offsetting losses from the drop in the long position's value.Moving together with Eyenovia Stock
| 0.67 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.94 | VINC | Vincerx Pharma Earnings Call This Week | PairCorr |
| 0.74 | ELVN | Enliven Therapeutics | PairCorr |
Moving against Eyenovia Stock
| 0.85 | AZN | AstraZeneca PLC ADR | PairCorr |
| 0.83 | SNY | Sanofi ADR | PairCorr |
| 0.78 | GILD | Gilead Sciences | PairCorr |
| 0.71 | LLY | Eli Lilly | PairCorr |
| 0.69 | GOSS | Gossamer Bio | PairCorr |
The ability to find closely correlated positions to Eyenovia could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eyenovia when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eyenovia - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eyenovia to buy it.
The correlation of Eyenovia is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eyenovia moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eyenovia moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eyenovia can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyenovia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Eyenovia Stock, please use our How to Invest in Eyenovia guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyenovia. If investors know Eyenovia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyenovia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (55.20) | Revenue Per Share | Quarterly Revenue Growth 0.356 | Return On Assets | Return On Equity |
The market value of Eyenovia is measured differently than its book value, which is the value of Eyenovia that is recorded on the company's balance sheet. Investors also form their own opinion of Eyenovia's value that differs from its market value or its book value, called intrinsic value, which is Eyenovia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyenovia's market value can be influenced by many factors that don't directly affect Eyenovia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyenovia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyenovia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyenovia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.